PPT-VTE Prophylaxis

Updates and Clarification to the Process This NetLearning is meant to clarify common confusion regarding the VTE Prophylaxis Process If you did not attend a Meaningful Use Class or take the original NetLearning Meaningful Use Mandatory NetLearning please view both to ensure that you understand the process completely. Charles . Levenback. , MD. Professor and Deputy Chair for Patient Care. Gynecologic Oncology Center Medical Director. Lisa Kidin, RN, MSN, MHA. Sr. Business Systems Analyst. Deep vein thrombosis (DVT):. Thromboembolism. N . Engl. J Med. 2012;366:1959-67. VTE Prevalence. Incidence . of DVT: 48 per 100,000. Incidence of PE: 23 per 100,000. Case-fatality rate. Inpatient: 12%. 1-year: 19%; 3-year: 30%. How Do Real-World Data Fit In? . Program Goals. VTE Is a Leading Cause of Death Worldwide. NOACs: VTE Clinical Trials. Real-World Data. XALIA. A Prospective, Noninterventional Study. EINSTEIN-DVT and XALIA: Outcomes. Decentralized Clinical Pharmacist. Department of Veteran Affairs. Tennessee Valley Healthcare System. Primary Thromboprophylaxis in . Ambulatory Cancer Patients:. Current Guidelines and Updated Evidence. November 7, 2014. Kendall Rogers, MD CPE FACP SFHM. Associate Professor and Chief. Patrick . Rendon. , MD. Assistant Professor . Associate Program Director. Division of Hospital Medicine. University of New Mexico . CHEST Guidelines 2016. Jennifer . Mah. , MD. March 2016. Case. A 44-year-old man is evaluated in follow-up for an episode of unprovoked left proximal leg deep venous thrombosis 3 months ago. Following initial anticoagulation with low-molecular-weight heparin, he began treatment with . The NIMC VTE Pilot. How to use the NIMC VTE prophylaxis section. Frequently asked questions. Extent of issue. In 2008:. VTE cases 14,716. Deaths 5,285. Working age 43%. Total inpatient costs $81.2m. Cancer and Thrombosis Management. Focus on Thrombosis Assessment, Prophylaxis, and Management in the Setting of Cancer and Associated Conditions. Program Chairman. Craig M. Kessler, MD. Professor of Medicine and Pathology. Objectives. Define VTE and discuss the incidence of VTE. Articulate risk factors for VTE. Discuss primary and secondary prevention. Review current guidelines. A Case…. A 12-year-old male with history of intractable epilepsy underwent right-sided craniotomy with grid placement for seizure mapping. He has a PICC line in place due to difficult IV access, and he is on bedrest. Pregnancy for women with complex needs. Maternity service update. Antenatal VTE assessment. Dr Lauren Ward – CCG clinical lead for preconception and antenatal care. Background – venous thromboembolism. Case Comprehensive Cancer Center. Venous . Thromboembolism . AND Cancer:. Prediction and prevention. DISCLOSURES. Consultant for . Sanofi. & Leo. Why You Should Care:. VTE AND MORTALITY. Khorana AA et al. . Dr Henan Dh Skheel. Department Of . Obs&Gyn. 2020. Venous . thromboembolism.  (. VTE) is a collective term that describes deep vein thrombosis (DVT) and pulmonary embolism (PE).. Venous thromboembolism is a leading cause of . Educational Slide Sets . American Society of Hematology 2022 for the Management of Venous Thromboembolism Disease. Author: . Dr Juan Carlos Serrano Casas, MD, Central University of Venezuela. Clínica Cancerológica de Norte de Santander (North Santander Oncology Clinic). By Cole Smith PharmD Candidate 2021. Outline:. Background on Coagulopathy and Cancer. Current VTE treatment guideline recommendations. Important trials influencing current recommendations. New Caravaggio Study (03/2020).